The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Novel therapies for the treatment of CLL, MCL and FL
Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes the results of recently completed clinical trials focused on novel therapies for treating chronic lymphocytic lymphoma (CLL), mantle cell lymphoma (MCL) and relapsed follicular lymphoma. The results from the BRIGHT study (NCT00877006) and STiL (NCT00991211) study, which were centred on treating patients with MCL with bendamustine and rituximab, are evaluated in this discussion. He also describes the promising results obtained from the GENUINE study (NCT02301156), which was focused on treating high-risk CLL with ibrutinib in combination with ublituximab. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
